Gosselar et al. analyzed the positive predictive value of DRE in the first three screening rounds at the Rotterdam section of the European Randomised Screening Prostate Cancer trial in 5040 prostate biopsies conducted in men referred due to a serum PSA level of 3.0 ng/mL or higher. The gene discussed is KLK3; the disease is prostate cancer.